CD274 and cancer: Three anti-PD-1 antibodies, nivolumab, pembrolizumab, and cemiplimab, have been approved by FDA for a wide range of cancers, along with three anti-PD-L1 monoclonal antibodies atezolizumab, durvalumab, and avelumab.